Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share
May 2, 2019 7:43 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.49), versus ($0.51) reported last year. Revenue for the quarter came in at $10.43 million, versus $7.47 million reported last year.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
... More